Natera (NASDAQ:NTRA) Stock: Insider Michael Burkes Brophy Sells 781 Shares

Natera, Inc. (NASDAQ:NTRA) CFO Michael Brophy sold 781 shares of the business’s stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $406.00, for a total value of $317,086.00. Following the completion of the transaction, the chief financial officer directly owned 50,856 shares of the company’s stock, valued at approximately $20,647,536. This trade represents a 1.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, October 30th, Michael Brophy sold 1,906 shares of Natera stock. The shares were sold at an average price of $425.55, for a total value of $811,098.30.
• On Wednesday, October 28th, Michael Brophy sold 1,198 shares of Natera stock. The shares were sold at an average price of $426.34, for a total value of $510,755.32.
• On Tuesday, August 4th, Michael Brophy sold 478 shares of Natera stock. The stock was sold at an average price of $274.22, for a total transaction of $131,077.16.
• On Monday, August 3rd, Michael Brophy sold 317 shares of Natera stock. The shares were sold at an average price of $267.99, for a total transaction of $84,952.83.

Natera Price Performance

NASDAQ:NTRA opened at $414.30 on Friday. The stock has a 50-day simple moving average of $377.06 and a two-hundred day simple moving average of $266.44. Natera, Inc. has a 52-week low of $181.00 and a 52-week high of $437.41.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company’s revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.74) earnings per share. As a group, equities analysts predict that Natera, Inc. will post -1.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on NTRA. JPMorgan Chase & Co. lifted their target price on shares of Natera from $360.00 to $460.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. BTIG Research increased their price target on Natera from $320.00 to $430.00 and gave the stock a “buy” rating in a research note on Tuesday. TD Cowen raised their price target on Natera from $340.00 to $480.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Roth Capital began coverage on Natera in a research report on Thursday, October 22nd. They issued a “buy” rating and a $475.00 price objective on the stock. Finally, Piper Sandler upped their price objective on Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $394.31.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera’s stock momentum remains strong after reaching a new 52-week high of approximately $436, reflecting continued investor enthusiasm for its oncology testing business and Signatera growth prospects. Natera reaches a fresh 52-week high
• Positive Sentiment: Recent ESMO oncology data, including 25 company presentations and additional Signatera evidence, could support broader clinical adoption and future revenue growth. Natera presents 25 ESMO abstracts
• Neutral Sentiment: Natera is scheduled to report third-quarter 2026 results after the market closes on November 5. The report will provide a near-term catalyst focused on Signatera testing volumes, pricing, reimbursement and profitability. Natera third-quarter results announcement
• Negative Sentiment: Several insiders sold shares this week, including the CEO, CFO and other executives. The transactions totaled roughly 11,500 shares, but each sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making the signal less concerning than discretionary selling. Natera insider selling
• Negative Sentiment: Zacks warned that Natera may report another quarterly loss and does not currently show the usual combination of positive estimate revisions and earnings momentum associated with a likely beat. With the stock trading well above its long-term moving averages and some valuation analyses estimating substantial downside to fair value, investors may be taking profits ahead of earnings. Natera earnings outlook

Hedge Funds Weigh In On Natera

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Provenance Wealth Advisors LLC bought a new stake in Natera in the 3rd quarter valued at $89,000. Factory Mutual Insurance Co. bought a new position in shares of Natera during the 3rd quarter valued at about $491,000. Aware Super Pty Ltd as trustee of Aware Super bought a new position in shares of Natera during the 3rd quarter valued at about $6,620,000. Greenleaf Trust purchased a new position in shares of Natera during the third quarter valued at about $240,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Natera during the third quarter valued at about $7,545,000. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.